Status:
RECRUITING
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Lead Sponsor:
Alice Chung
Conditions:
Breast Cancer
Axillary Nodal Disease
Eligibility:
FEMALE
45+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated...
Eligibility Criteria
Inclusion
- Women age ≥ 45
- Clinical T1-2N0 ER+ invasive breast cancer
- US detected biopsy proven axillary nodal disease
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion
- Palpable nodes on physical exam
- Her2+ or ER- invasive breast cancer
- Extranodal extension \> 3 mm on nodal biopsy
- More than 2 suspicious nodes on preoperative imaging
Key Trial Info
Start Date :
April 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2031
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06092892
Start Date
April 7 2024
End Date
April 1 2031
Last Update
December 10 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States, 90048
2
CS Cancer at Huntington Cancer Center
Pasadena, California, United States, 91105
3
CS Cancer at Valley Oncology Medical Group
Tarzana, California, United States, 91356